Skip to main content
. 2021 Apr 6;12(4):356. doi: 10.1038/s41419-021-03626-7

Fig. 7. miR-145-5p targets CDCA3 to sustain HCC cell tumorigenicity.

Fig. 7

A Schematic of CDCA3 3′ UTR wild-type (WT) and mutant (Mut) luciferase reporter vectors. Relative luciferase activities analyzed in 293 T cells co-transfected with the miR-145-5p plasmid or miR-NC and luciferase reporter vectors CDCA3 3′ UTR (WT) or CDCA3 3′ UTR (Mut) (*P < 0.05; n = 3). B Western blot analysis indicating that miR-145-5p downregulates CDCA3 (**P < 0.01; ***P < 0.001; n = 4). C, D HCCLM3 and HepG2 cell viability following co-transfection with siRNA-CDCA3 and miR-145-5p inhibitor, measured by WST-1 assays (**P < 0.01; n = 4). E, F Proliferative capacity of HCCLM3 and HepG2 cells co-transfected with siRNA-CDCA3 and miR-145-5p inhibitor, evaluated by colony formation assay (**P < 0.01; ***P < 0.001; n = 4). G, H The influence on cell migration and invasion of HCCLM3 and HepG2 cells transfected with siRNA-CDCA3 and miR-145-5p inhibitor, assessed by transwell migration and Matrigel invasion assays (**P < 0.01; ***P < 0.001; n = 4).